Korro Bio (KRRO) Non-Current Assets (2018 - 2026)
Korro Bio's (KRRO) quarterly Non-Current Assets came in at $63.5 million in Q1 2026, down 21.63% YoY from $81.0 million in Q1 2025, and up 103.83% on a QoQ basis from $31.1 million in Q4 2025.
Korro Bio (KRRO) Non-Current Assets (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Non-Current Assets data on file, last reported at $63.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 21.63% year-over-year to $63.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.7 million (down 33.11% YoY) and the FY2025 annual result came in at $31.1 million, down 67.13% from the prior year.
- Non-Current Assets improved to $63.5 million in Q1 2026, from $31.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $94.7 million in Q4 2024 to a low of $3.8 million in Q3 2023.
- A 5-year average of $52.3 million and a median of $48.9 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 89.01% — and 2024, when it jumped 2258.02%.
- Tracing KRRO's Non-Current Assets over 5 years: stood at $16.7 million in 2022, then jumped by 193.75% to $48.9 million in 2023, then surged by 93.54% to $94.7 million in 2024, then plunged by 67.13% to $31.1 million in 2025, then jumped by 103.83% to $63.5 million in 2026.
- The last three Non-Current Assets figures came in at $63.5 million (Q1 2026), $31.1 million (Q4 2025), and $63.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 42.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.82 Mn |
| Mar 31, 2026 | 63.46 Mn |
| Dec 31, 2025 | 31.13 Mn |
| Sep 30, 2025 | 63.32 Mn |
| Jun 30, 2025 | 77.79 Mn |
| Mar 31, 2025 | 80.97 Mn |
| Dec 31, 2024 | 94.71 Mn |
| Sep 30, 2024 | 90.76 Mn |
| Jun 30, 2024 | 85.96 Mn |
| Mar 31, 2024 | 52.33 Mn |
| Dec 31, 2023 | 48.94 Mn |
| Sep 30, 2023 | 3.85 Mn |
| Jun 30, 2023 | 31.00 Mn |
| Mar 31, 2023 | 32.21 Mn |
| Dec 31, 2022 | 16.66 Mn |
| Sep 30, 2022 | 35.02 Mn |
| Jun 30, 2022 | 36.24 Mn |
| Mar 31, 2022 | 45.00 Mn |
| Dec 31, 2021 | 50.61 Mn |
| Sep 30, 2021 | 52.28 Mn |